Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1992 1
1993 4
1994 5
1995 5
1996 2
1997 1
1998 2
1999 5
2000 3
2001 8
2002 1
2003 9
2004 4
2005 9
2006 4
2007 8
2008 10
2009 12
2010 10
2011 12
2012 11
2013 12
2014 15
2015 13
2016 10
2017 10
2018 11
2019 19
2020 10
2021 8
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Unresectable Adult Hepatocellular Carcinoma"
Page 1
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Yang X, et al. Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8. Hepatol Int. 2023. PMID: 36753026 Free PMC article.
INTRODUCTION: Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resectable hepatocellular carcinoma (uHCC). This study aimed to investigate the real-world efficacy of and prognostic factors …
INTRODUCTION: Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resecta …
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Salem R, et al. Hepatology. 2021 Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11. Hepatology. 2021. PMID: 33739462 Free PMC article.
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. The aim of the LEGACY (Local radioEmbolization using Glass Microspheres for the Assessment of Tumor Control with Y-90) s …
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresecta …
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Hong TS, et al. J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14. J Clin Oncol. 2016. PMID: 26668346 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). ...Sample size was calculated to demonstrate > 80% local control (LC) defined by R …
PURPOSE: To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma ( …
External beam radiotherapy for unresectable hepatocellular carcinoma.
Abdel-Rahman O, Elsayed Z. Abdel-Rahman O, et al. Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2. Cochrane Database Syst Rev. 2017. PMID: 28267205 Free PMC article. Review.
BACKGROUND: Hepatocellular carcinoma is the most common liver neoplasm, the sixth most common cancer worldwide, and the third most common cause of cancer mortality. ...While surgical resection and liver transplantation are the main curative treatments, only around 2 …
BACKGROUND: Hepatocellular carcinoma is the most common liver neoplasm, the sixth most common cancer worldwide, and the third …
Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience.
Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, Singh V, Dhiman RK, Chawla YK, Khandelwal N. Kalra N, et al. Cardiovasc Intervent Radiol. 2019 Apr;42(4):584-590. doi: 10.1007/s00270-019-02164-2. Epub 2019 Jan 29. Cardiovasc Intervent Radiol. 2019. PMID: 30697637
PURPOSE: To evaluate the efficacy and safety of irreversible electroporation (IRE) in the treatment of unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A retrospective study was conducted from September 2014 to June 2017. ...The tumor-relat …
PURPOSE: To evaluate the efficacy and safety of irreversible electroporation (IRE) in the treatment of unresectable hepatocellular …
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.
Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Chadha AS, et al. Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16. Radiother Oncol. 2019. PMID: 30935582 Free PMC article.
BACKGROUND AND PURPOSE: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC). METHODS AND METHODS: Forty-six patients with HCC, Child-Pugh class of …
BACKGROUND AND PURPOSE: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized …
Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.
Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Sanford NN, et al. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):64-72. doi: 10.1016/j.ijrobp.2019.01.076. Epub 2019 Jan 23. Int J Radiat Oncol Biol Phys. 2019. PMID: 30684667
PURPOSE: Ablative radiation therapy is increasingly being used for hepatocellular carcinoma (HCC) resulting in excellent local control rates; however, patients without evidence of disease progression often die from liver failure. ...We therefore sought to com …
PURPOSE: Ablative radiation therapy is increasingly being used for hepatocellular carcinoma (HCC) resulting in excellent lo …
Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma.
Song Z, Ye J, Wang Y, Li Y, Wang W. Song Z, et al. J Cancer Res Ther. 2019;15(7):1553-1560. doi: 10.4103/jcrt.JCRT_629_19. J Cancer Res Ther. 2019. PMID: 31939437 Free article.
PURPOSE: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between February 2013 and March 2019, 57 patients with 108 unresectable HCC …
PURPOSE: This study aimed to retrospectively assess the outcome of interstitial iodine-125 brachytherapy for unresectable hepatoce …
Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: Experience from the Society of Pediatric Liver Transplantation (SPLIT).
Boster JM, Superina R, Mazariegos GV, Tiao GM, Roach JP, Lovell MA, Greffe BS, Yanni G, Leung DH, Elisofon SA, McDiarmid SV, Gupta NA, Lobritto SJ, Lemoine C, Stoll JM, Vitola BE, Daniel JF, Sayed BA, Desai DM, Martin AE, Amin A, Anand R, Anderson SG, Sundaram SS. Boster JM, et al. Am J Transplant. 2022 May;22(5):1396-1408. doi: 10.1111/ajt.16945. Epub 2022 Jan 22. Am J Transplant. 2022. PMID: 34990053 Free article.
Management of unresectable pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) remains challenging. ...Judicious patient selection is critical to distinguish tumors that are potentially resectable; simultaneously, we must advocate for patients wi …
Management of unresectable pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) remains challenging. ...Jud …
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R, Siegel E, Makhoul I, Williamson S. Govindarajan R, et al. Am J Clin Oncol. 2013 Jun;36(3):254-7. doi: 10.1097/COC.0b013e318248d83f. Am J Clin Oncol. 2013. PMID: 22643560 Clinical Trial.
PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not candidates for local therapy. ...CONCLUSIONS: The 28% progression-free survival rate at 27 weeks was not significantly higher than th …
PURPOSE: To evaluate the combination of erlotinib and bevacizumab in subjects with hepatocellular carcinoma (HCC) who are not …
214 results